csirt@kutim:~/threat-intel/cve/CVE-2026-33534

Katalog CVE

CVSS 4.3 · Medium EPSS 1,7%

Kerentanan Server-Side Request Forgery (SSRF) pada espocrm. Skor CVSS 3.1 4.3 (Medium) menurut github.com.

Deskripsi (NVD)

EspoCRM is an open source customer relationship management application. Versions 9.3.3 and below have an authenticated Server-Side Request Forgery (SSRF) vulnerability that allows bypassing the internal-host validation logic by using alternative IPv4 representations such as octal notation (e.g., 0177.0.0.1 instead of 127.0.0.1). This is caused by HostCheck::isNotInternalHost() function relying on PHP's filter_var(..., FILTER_VALIDATE_IP), which does not recognize alternative IP formats, causing the validation to fall through to a DNS lookup that returns no records and incorrectly treats the host as safe, however the cURL subsequently normalizes the address and connects to the loopback destination. Through the confirmed /api/v1/Attachment/fromImageUrl endpoint, an authenticated user can force the server to make requests to loopback-only services and store the fetched response as an attachment. This vulnerability is distinct from CVE-2023-46736 (which involved redirect-based SSRF) and may allow access to internal resources reachable from the application runtime. This issue has been fixed in version 9.3.4.

Rincian

Terbit di NVD
13 April 2026
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
4.3 (Medium), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-918: Server-Side Request Forgery (SSRF)
EPSS (30 hari)
1,7% peluang dieksploitasi; lebih tinggi dari 76,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
espocrm espocrm Semua versi sebelum 9.3.4

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.